Clinical benefit mechanism of alteplase intravenous thrombolysis on different subtypes of acute ischemic stroke

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600120870

Enrollment

Unknown

Registered

2026-03-20

Start date

2023-09-12

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebrovascular disease

Interventions

Alteplase intravenous thrombolysis group:Standard-dose intravenous alteplase thrombolysis (0.9 mg/kg, 10% bolus followed by 1-hour infusion, maximum 90 mg) plus standard acute stroke care in eligible

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Diagnosed with acute ischemic stroke, with onset time (defined as the 'last time seen normal') to medication time 5 and <= 25; 5. The subject or their guardian voluntarily agrees to participate and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Previous intracranial hemorrhage, including suspected subarachnoid hemorrhage, history of head trauma within the past 3 months, gastrointestinal or urinary system bleeding within the past 3 weeks, major surgery within the past 2 weeks, or arterial puncture in a site difficult to compress for hemostasis within the past week; 2. History of cerebral infarction or myocardial infarction within the past 3 months, excluding old lacunar infarctions; 3. Severe heart, liver, or kidney dysfunction; 4. Oral anticoagulant use with an international normalized ratio (INR) >1.7 or prothrombin time (PT) >15s, or treatment with low molecular weight heparin within the past 24 hours; 5. Platelet count 22.22 mmol/L; 6. Pre-thrombolysis systolic blood pressure >=180 mmHg or diastolic blood pressure >=100 mmHg; 7. Intracranial tumor, giant intracranial aneurysm; 8. Aortic arch dissection; 9. Pregnancy or non-cooperation.

Design outcomes

Primary

Measure	Time frame
90+/-7-day Modified Rankin Scale (mRS) Score;TOAST Etiological Classification;Early Neurological Deterioration;	—

Secondary

Measure	Time frame
National Institutes of Health Stroke Scale (NIHSS) Score;7±2-day/pre-discharge mRS Score;90±7-day All-Cause Mortality;Onset-to-Thrombolysis Time (ONT);	—

Countries

China

Contacts

Public ContactGuan Yuhua

People's Hospital of Bayingol Mongolian Autonomous Prefecture

yh2022guan@163.com+86 150 9946 2459

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026